TABLE 1

Baseline characteristics in INPULSIS® by annual rate of change in FVC in INPULSIS®

Improvement or no decline in FVCDecline in FVC
NintedanibPlaceboNintedanibPlacebo
Subjects n15838480385
Age years66.3±7.967.6±8.266.7±8.266.9±7.9
Male126 (79.7)31 (81.6)381 (79.4)303 (78.7)
Race
 White99 (62.7)24 (63.2)261 (54.4)224 (58.2)
 Black1 (0.6)0 (0.0)1 (0.2)0 (0.0)
 Asian38 (24.1)11 (28.9)156 (32.5)117 (30.4)
 Missing#20 (12.7)3 (7.9)62 (12.9)44 (11.4)
Former or current smoker130 (82.3)28 (73.7)334 (69.6)273 (70.9)
Weight kg82.6±15.483.9±18.078.1±16.878.1±16.3
Time since diagnosis of IPF years1.6±1.41.5±1.11.7±1.41.6±1.3
FVC mL2850±7822949±8272669±7442706±806
FVC % pred81.6±18.184.4±19.879.1±17.478.8±18.0
DLCO % pred47.5±12.350.7±17.147.4±13.946.6±12.9
Diagnostic subgroup
 No honeycombing on HRCT and no biopsy50 (31.7)8 (21.1)163 (34.0)117 (30.4)
 Honeycombing on HRCT and/or confirmation of UIP  by biopsy108 (68.4)30 (79.0)317 (66.0)268 (69.6)

Data are presented as mean±sd or n (%), unless otherwise stated. FVC: forced vital capacity; IPF: idiopathic pulmonary fibrosis; DLCO: diffusing capacity of the lung for carbon monoxide; HRCT: high-resolution computed tomography; UIP: usual interstitial pneumonia. #: in France, regulations did not permit the collection of data on race.